We are live on ! Find out more
Daiwa Securities Group

Daiwa Securities Group Portfolio holdings

AUM $34.8B
1-Year Est. Return 20.7%
This Fund
S&P 500
This Quarter Est. Return
-4.66%
1 Year Est. Return
+20.7%
3 Year Est. Return
+66.64%
5 Year Est. Return
+79.21%
10 Year Est. Return
+192.59%
AUM
$12.5B
AUM Growth
-$1.66B
Cap. Flow
-$1.45B
Cap. Flow %
-11.6%
Top 10 Hldgs %
32.88%
Holding
1,206
New
194
Increased
593
Reduced
261
Closed
41

Sector Composition

Rank Sector Weight
1 Real Estate 73.13%
2 Industrials 4.58%
3 Technology 4.24%
4 Financials 3.1%
5 Healthcare 2.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ACOR
1051
DELISTED
Acorda Therapeutics
ACOR
$6K ﹤0.01%
+2
New +$5.99K
GHDX
1052
DELISTED
Genomic Health, Inc.
GHDX
$6K ﹤0.01%
+192
New +$6.37K
CSRA
1053
DELISTED
CSRA Inc.
CSRA
$6K ﹤0.01%
146
AUO
1054
DELISTED
AU Optronics Corp
AUO
$6K ﹤0.01%
+1,400
New +$6.42K
AMPH icon
1055
Amphastar Pharmaceuticals
AMPH
$843M
$5K ﹤0.01%
+254
New +$4.78K
COLL icon
1056
Collegium Pharmaceutical
COLL
$1.16B
$5K ﹤0.01%
+180
New +$4.29K
LXRX icon
1057
Lexicon Pharmaceuticals
LXRX
$1.03B
$5K ﹤0.01%
+583
New +$5.39K
MGNX icon
1058
MacroGenics
MGNX
$250M
$5K ﹤0.01%
+203
New +$4.93K
NTLA icon
1059
Intellia Therapeutics
NTLA
$1.52B
$5K ﹤0.01%
+234
New +$5.75K
RGNX icon
1060
Regenxbio
RGNX
$632M
$5K ﹤0.01%
+172
New +$5.01K
TVTX icon
1061
Travere Therapeutics
TVTX
$5.35B
$5K ﹤0.01%
+217
New +$5.17K
ATNX
1062
DELISTED
Athenex, Inc. Common Stock
ATNX
$5K ﹤0.01%
+16
New +$5.08K
FLXN
1063
DELISTED
Flexion Therapeutics, Inc.
FLXN
$5K ﹤0.01%
+207
New +$5.05K
LMNX
1064
DELISTED
Luminex Corp
LMNX
$5K ﹤0.01%
+243
New +$4.97K
BOLD
1065
DELISTED
Audentes Therapeutics, Inc
BOLD
$5K ﹤0.01%
+165
New +$5.59K
ALDR
1066
DELISTED
Alder Biopharmaceuticals
ALDR
$5K ﹤0.01%
+374
New +$5.41K
ADAP
1067
DELISTED
Adaptimmune Therapeutics
ADAP
$4K ﹤0.01%
+323
New +$2.83K
AMRN
1068
Amarin Corp
AMRN
$286M
$4K ﹤0.01%
+74
New +$5.49K
ANIP icon
1069
ANI Pharmaceuticals
ANIP
$1.78B
$4K ﹤0.01%
+64
New +$4.06K
CHRS icon
1070
Coherus Oncology
CHRS
$227M
$4K ﹤0.01%
+320
New +$3.5K
GERN icon
1071
Geron
GERN
$956M
$4K ﹤0.01%
+880
New +$2.38K
KPTI icon
1072
Karyopharm Therapeutics
KPTI
$166M
$4K ﹤0.01%
+17
New +$3.39K
NVAX icon
1073
Novavax
NVAX
$1.27B
$4K ﹤0.01%
+87
New +$3.5K
QURE icon
1074
uniQure
QURE
$2.67B
$4K ﹤0.01%
+170
New +$3.71K
VNDA icon
1075
Vanda Pharmaceuticals
VNDA
$319M
$4K ﹤0.01%
+248
New +$4.15K

Similar funds

Daiwa Securities Group's Q1 2018 Portfolio in Review

As of Q1 2018, Daiwa Securities Group held 1,206 positions worth $12.5B, down 12% from $14.1B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Daiwa Securities Group withdrew a net $1.45B in Q1 2018, closing 41 positions and reducing 261 holdings. Its most notable exit was Anthem, Inc., an estimated $25.2M position sold in full.

By sector, the portfolio is most concentrated in Real Estate at 73% of assets, down from 77% a quarter earlier, followed by Industrials and Technology.

Against the trend, Daiwa Securities Group opened a new position in Supernus Pharmaceuticals worth $3.16M.

  • Daiwa Securities Group's largest Q1 2018 buy was Supernus Pharmaceuticals: 68,983 shares worth $3.16M.
  • Daiwa Securities Group added most to Boston Properties in Q1 2018, an estimated $165M increase.
  • Daiwa Securities Group's biggest Q1 2018 reduction was Simon Property Group, cutting an estimated $275M.
  • Daiwa Securities Group fully exited Anthem, Inc. in Q1 2018, selling an estimated $25.2M.
  • Daiwa Securities Group's ten largest holdings make up 33% of its $12.5B portfolio in Q1 2018.
  • Daiwa Securities Group opened 194 new positions and closed 41 in Q1 2018.
  • Daiwa Securities Group's portfolio value fell 12% quarter-over-quarter to $12.5B.

Based on Daiwa Securities Group's 13F filing for Q1 2018, filed 2 May 2018.